TY - JOUR
T1 - Development of the national network of depression centers mood outcomes program
T2 - A multisite platform for measurement-based care
AU - Zandi, Peter P.
AU - Wang, Yu Hsun
AU - Patel, Paresh D.
AU - Katzelnick, David
AU - Turvey, Carolyn L.
AU - Wright, Jesse H.
AU - Ajilore, Olusola
AU - Coryell, William
AU - Schneck, Christopher D.
AU - Guille, Constance
AU - Saunders, Erika F.H.
AU - Lazarus, Sophie A.
AU - Cuellar, Valeria A.
AU - Selvaraj, Sudhakar
AU - Dill Rinvelt, Patricia
AU - Greden, John F.
AU - Raymond DePaulo, J.
N1 - Funding Information:
This work was made possible by a research collaboration supported by the National Network of Depression Centers. The authors thank Edie Douglas, M.P.H., Kara Glazer, Marjorie Gresbrink, Deanna Hofschulte, C.C.R.P., Dane Larsen, Martha Shaw, Dana Steidtmann, Ph.D., and Carol Wahl. Altarum provided technical expertise to build and maintain the mood outcomes system, including operational support from Rachelle May-Gentile, Mike Grim, and Ryan Callahan. The authors also thank Katie Hurtis and members of the Epic staff for their ongoing assistance and support during this effort. Dr. Katzelnick has commercial interests with Principle Healthcare Technology Systems. Dr. Wright has an equity interest in Empower Interactive and Mindstreet; this conflict of interest is managed with an agreement with the University of Louisville. He receives book royalties from American Psychiatric Press, Inc., Guilford Press, and Simon and Schuster. Dr. Ajilore is the co-founder and chief medical officer of Keywise, Inc., is on the Advisory Board of both Blueprint Health and Embodied Labs, and is a consultant for Quartet Health. Dr. Guille is a member of Sage Therapeutics advisory board and speakers bureau. Dr. Saunders received an honorarium for work as an associate editor from the Journal of Clinical Psychiatry. Dr. Selvaraj received speaking honoraria from Global Medical Education and honoraria from British Medical Journal Publishing Group, owns shares at Flow Med Tech, and is a site investigator for a clinical trial by COMPASS Pathways Limited. Dr. Greden is a consultant for Clarigent, Genomind, Med-IQ, Inc., MoldX, and Sage Therapeutics and is involved in a pharmacogenomics study funded by AssureX and Myriad Neuroscience. He is involved commercially with Janssen Pharmaceutical, Naurex (Allergan) Pharmaceutical, Cerecor Pharmaceutical, and NeuralStem. Dr. DePaulo is an unpaid consultant for the Assurex Health/Myriad Company; he owns stock in CVS, which now owns Aetna Insurance. The other authors report no financial relationships with commercial interests. Received September 27, 2019; revision received October 23, 2019; accepted October 31, 2019; published online January 21, 2020.
Funding Information:
This work was made possible by a research collaboration supported by the National Network of Depression Centers. The authors thank Edie Douglas, M.P.H., Kara Glazer, Marjorie Gresbrink, Deanna Hofschulte, C.C.R.P., Dane Larsen, Martha Shaw, Dana Steidtmann, Ph.D., and Carol Wahl. Altarum provided technical expertise to build and maintain the mood outcomes system, including operational support from Rachelle May-Gentile, Mike Grim, and Ryan Callahan. The authors also thank Katie Hurtis and members of the Epic staff for their ongoing assistance and support during this effort.
Publisher Copyright:
© 2020 American Psychiatric Association. All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Objectives: Mood disorders are among the most burdensome public health concerns. The National Network of Depression Centers (NNDC) is a nonprofit consortium of 26 leading clinical and academic member centers in the United States providing care for patients with mood disorders, including depression and bipolar disorder. The NNDC has established a measurement-based care program called the Mood Outcomes Program whereby participating sites follow a standard protocol to electronically collect patient-reported outcome assessments on depression, anxiety, and suicidal ideation in routine clinical care. This article describes the approaches taken to develop and implement the program. Methods: Since 2015, eight pilot sites have implemented the program and followed more than 10,000 patients. This pilot study presents descriptive statistics based on the first 24-month period of data collection. Results: In this sample, 58.6% of patients with bipolar disorder (N=849) and 57.5% of patients with unipolar depression (N=3,998) remained symptomatic at follow-up. Lifetime rates of planned or actual suicide attempts were high, ranging from 27.6% for patients with unipolar mood disorders to 33.5% for patients with bipolar disorder. Men, unmarried individuals, and those with comorbid anxiety had a poorer longitudinal course. This initial snapshot of clinical burden is consistent with public health data indicating that mood disorders are severely debilitating. Conclusions: This study demonstrates the potential of the Mood Outcomes Program to create a nationwide “learning health system” for mood disorders. This goal will be further realized as the program expands in reach and scope across additional NNDC sites.
AB - Objectives: Mood disorders are among the most burdensome public health concerns. The National Network of Depression Centers (NNDC) is a nonprofit consortium of 26 leading clinical and academic member centers in the United States providing care for patients with mood disorders, including depression and bipolar disorder. The NNDC has established a measurement-based care program called the Mood Outcomes Program whereby participating sites follow a standard protocol to electronically collect patient-reported outcome assessments on depression, anxiety, and suicidal ideation in routine clinical care. This article describes the approaches taken to develop and implement the program. Methods: Since 2015, eight pilot sites have implemented the program and followed more than 10,000 patients. This pilot study presents descriptive statistics based on the first 24-month period of data collection. Results: In this sample, 58.6% of patients with bipolar disorder (N=849) and 57.5% of patients with unipolar depression (N=3,998) remained symptomatic at follow-up. Lifetime rates of planned or actual suicide attempts were high, ranging from 27.6% for patients with unipolar mood disorders to 33.5% for patients with bipolar disorder. Men, unmarried individuals, and those with comorbid anxiety had a poorer longitudinal course. This initial snapshot of clinical burden is consistent with public health data indicating that mood disorders are severely debilitating. Conclusions: This study demonstrates the potential of the Mood Outcomes Program to create a nationwide “learning health system” for mood disorders. This goal will be further realized as the program expands in reach and scope across additional NNDC sites.
UR - http://www.scopus.com/inward/record.url?scp=85084189785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084189785&partnerID=8YFLogxK
U2 - 10.1176/appi.ps.201900481
DO - 10.1176/appi.ps.201900481
M3 - Article
C2 - 31960777
AN - SCOPUS:85084189785
SN - 1075-2730
VL - 71
SP - 456
EP - 464
JO - Psychiatric Services
JF - Psychiatric Services
IS - 5
ER -